Showing 1001-1010 of 2019 results for "".
DermWireTV: AbbVie's Science of Skin Panel, Monkeypox Warning, Recommendations on Skin Cancer Detection Devices, UV Filters and Aquatic Life
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-abbvies-science-of-skin-panel-monkeypox-warning-recommendations-on-skin-cancer-detection-devices-uv-filters-and-aquatic-life/20131/“The Science of Skin: United Beyond the Surface” program sponsored by AbbVie brings together leading dermatologists and patients or caregivers of patients with dermatologic disease to explore the burden of skin diseases on diverse populations and the need for optimized treatment approaches. Seemal DSunscreen Ratings, Restylane Lyft for Hands, NPF, SCF News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-sunscreen-ratings-restylane-lyft-for-hands-npf-scf-news/18305/Both Consumer Reports and the Environmental Working Group have issued sunscreen rankings, and while some products shine, many products may underperform. FDA issued warnings to several companies illegally marketing dietary supplements that make unproven drug claims about protecting consumers from sunAD Impact, Allofill Comes to Market, GPA Launches
https://practicaldermatology.com/topics/psoriasis/dermwiretv-ad-impact-allofill-comes-to-market-gpa-launches/18567/From sleep disruptions or negative impact on the ability to work to feelings of depression and anxiety, atopic dermatitis can have significant effects on adults, new research suggests. In fact, more than half of respondents to a Harris Poll say that AD has negatively impacted their daily lives. DoriKamedis Botanically-based Regimen for Dandruff
https://practicaldermatology.com/topics/general-topics/kamedis-botanically-based-regimen-for-dandruff/18579/Kamedis brings innovation to the treatment of seborrheic dermatitis (SD, also called dandruff) with a botanically-based 2-step hair care system. The two-step Kamedis system for seborrheic dermatitis consists of SEBOMedis Anti-Dandruff Shampoo and Scalp Lotion. Botanical ingredients include indigo (IDr. Kauvar Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-kauvar-discusses-experience-with-gemini-laser/19469/“Treating with the Gemini is very well accepted by patients because both components of the Gemini, the 1064 and the 532nm, are non-invasive lasers. So there's really no real downtime and no recuperation, and the results are predictable in our hands, and patients are very satisfied with their treatDermwireTV — Revance’s Neurotoxin Promising, Celebs Fight Melanoma with L’Oreal
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-revance-rsquo-s-neurotoxin-promising-celebs-fight-melanoma-with-l-rsquo-oreal/19138/In this weeks DermwireTV, patient safety is explored, L'Oreal supports melanoma research and Revance reports positive data for novel neurotoxin.DermwireTV — Nestle acquires Galderma; Dermatologic procedures surge
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-nestle-acquires-galderma-dermatologic-procedures-surge/19157/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine: Nestle acquires Galderma, dermatologic procedures surge, and we look ahead to the annual meeting in Denver. #DermWireDermwireTV — A big name is getting bigger; ICD-10 looms
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-a-big-name-is-getting-bigger-icd-10-looms/19163/In this premiere edition of DermWireTV, from the publishers of Practical Dermatology® magazine, we take a look at the latest acquisition by Valeant Pharmaceuticals, Inc., explore new data for Galderma's Mirvaso for rosacea, and get insights on the ICD-10 code set transition. #DermWireDermwireTV — Sun Rises, ICD-10 is Delayed…Again
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-sun-rises-icd-10-is-delayed-again/19139/In this week's DermwireTV, Sun acquires Ranbaxy, ICD-10 gets unexpectedly delayed, and Murad Alam recaps the ASLMS conference.DermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's lates